Cardiawave is presenting the 30-day follow-up results from its “Valvosoft® Pivotal Study” on the treatment of severe symptomatic aortic valve stenosis

2024-04-05

At the 73rd Annual Conference of the ACC (American College of Cardiology) April 6–8, 2024, Atlanta (GA) LEVALLOIS-PERRET, France--(BUSINESS WIRE)-- Cardiawave SA, a French medtech company that has developed an innovative Non-Invasive focused Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, will present the 30-day follow-up results for 60 patients enrolled in its European pivotal study to the 73rd annual conference of the American College of Cardiology in Atlanta, Georgia. This is a leading event in the cardiovascular medicine calendar, which brings together specialists from around the world to discuss the latest advances, research results and clinical innovations in the field of cardiology. Prof. Eric Van Belle, cardiologist at Lille University Hospital, one of the principal investigators for the European pivotal study, commented: “I’m very proud to present the excellent results obtained using Cardiawave’s NIUT device to treat patients with severe symptomatic aortic valve stenosis, leading to a significant improvement in their condition and a better quality of life. This ACC.24 presentation represents a major contribution to the advance of science and will open up innovative therapeutic strategies for cardiology patients.” A summary of the poster session will be published on the Journal of the American College of Cardiology’s website. Presentation title: QUALITY OF LIFE ASSESSMENT AT 30-DAYS FOLLOW-UP OF THE VALVOSOFT® PIVOTAL STUDY ON SEVERE AORTIC VALVE STENOSE PATIENTS" (control number 16930) Time and date: April 8, 2024 - 9:32 a.m.–9:42 a.m. EDT The results of the Cardiawave First-in-Human “Valvosoft® FIM Study” were published in The Lancet in November 2023: (23)01518-0/fulltext About Cardiawave : © Cardiawave, 2024

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构